Effect of postoperative radiotherapy in women with localized pure mucinous breast cancer after lumpectomy: a population-based study.


Journal

Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111

Informations de publication

Date de publication:
07 Jul 2022
Historique:
received: 30 06 2021
accepted: 13 06 2022
entrez: 7 7 2022
pubmed: 8 7 2022
medline: 12 7 2022
Statut: epublish

Résumé

Pure mucinous breast cancer is a rare subtype of invasive breast cancer with favorable prognosis, in which the effect of postoperative radiotherapy remains unclear. We aimed to investigate the prognostic value of postoperative radiotherapy in women with localized pure mucinous breast cancer after lumpectomy. We conducted a retrospective cohort study to compare the effectiveness of postoperative radiotherapy (RT) and omitting postoperative radiotherapy (non-RT) in patients with first primary T1-2N0M0 (T ≤ 3 cm) pure mucinous breast cancer who underwent lumpectomy between 1998 and 2015 using the Surveillance, Epidemiology, and End Results (SEER) database. Breast cancer-specific survival (BCSS) was compared between RT and non-RT groups using Kaplan-Meier method and Cox proportional hazards regression model. Propensity score matching (PSM) was carried out to balance cohort baselines. In addition, an exploratory analysis was performed to verify the effectiveness of RT in subgroup patients. Of 7832 eligible patients, 5352 (68.3%) underwent lumpectomy with postoperative RT, 2480 (31.7%) received lumpectomy without postoperative RT. The median follow-up duration was 92 months. The median age was 66 years in the RT group and 76 years in the non-RT group.The 15-year BCSS was 94.39% (95% CI, 93.08% to 95.35%) in the RT group versus 91.45%(95% CI, 88.93% to 93.42%) in the non-RT group (P < 0.001). The adjusted hazard ratio for BCSS was 0.64 (95% CI, 0.49 to 0.83; P = 0.001) for RT group versus non-RT group. After propensity score matching, similar results were yielded. Adjuvant RT reduced the 15-year risk of breast cancer death from 7.92% to 6.15% (P = 0.039). The adjusted hazard ratio for BCSS were 0.66 (95%CI, 0.47 to 0.92; P = 0.014) for RT group versus non-RT group. The benefit of RT was well consistent across subgroup patients. Among women with T1-2N0M0 (tumor size ≤ 3 cm) pure mucinous breast cancer, the addition of RT after lumpectomy was significantly associated with a reduced incidence of breast cancer death compared with non-RT, and the magnitude of benefit may be modest. This suggests that postoperative RT is recommended in the treatment of localized pure mucinous breast cancer.

Identifiants

pubmed: 35799256
doi: 10.1186/s13014-022-02082-7
pii: 10.1186/s13014-022-02082-7
pmc: PMC9264504
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

119

Subventions

Organisme : natural science foundation of zhejiang province
ID : Y19H160283

Informations de copyright

© 2022. The Author(s).

Références

Ann Surg Oncol. 2012 Sep;19(9):3019-27
pubmed: 22451233
J Cancer. 2018 Aug 6;9(18):3216-3224
pubmed: 30271480
J Breast Cancer. 2011 Dec;14(4):308-13
pubmed: 22323918
Breast Cancer Res Treat. 2002 Dec;76(3):255-60
pubmed: 12462386
J Surg Oncol. 2012 May;105(6):586-90
pubmed: 22065479
Lancet. 2005 Dec 17;366(9503):2087-106
pubmed: 16360786
PLoS One. 2016 May 27;11(5):e0155132
pubmed: 27232881
Am J Clin Pathol. 1987 Feb;87(2):155-60
pubmed: 3028120
Breast Cancer Res Treat. 2008 Oct;111(3):541-7
pubmed: 18026874
J Clin Oncol. 1999 Aug;17(8):2326-33
pubmed: 10561294
J Clin Oncol. 2010 Jun 1;28(16):2784-95
pubmed: 20404251
Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1899-905
pubmed: 17035397
PLoS One. 2016 Oct 19;11(10):e0164921
pubmed: 27760180
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
Breast J. 2016 Sep;22(5):529-34
pubmed: 27261206
Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):152-9
pubmed: 15093911
J Clin Oncol. 2012 Mar 1;30(7):729-34
pubmed: 22291085
Am J Surg. 2007 Oct;194(4):527-31
pubmed: 17826073
Jpn J Clin Oncol. 2002 Feb;32(2):64-7
pubmed: 11948231
Clin Breast Cancer. 2019 Feb;19(1):e66-e73
pubmed: 30396812
Radiat Oncol. 2019 Nov 4;14(1):190
pubmed: 31685005
J Clin Oncol. 1999 May;17(5):1442-8
pubmed: 10334529
Ann Surg Oncol. 2019 Jul;26(7):2166-2174
pubmed: 30977015
J Natl Cancer Inst. 2019 Jul 1;111(7):737-741
pubmed: 30649385
J Pathol. 2010 Nov;222(3):282-98
pubmed: 20815046
Am J Clin Pathol. 1982 Dec;78(6):806-16
pubmed: 7148748
Int J Cancer. 2007 Jul 1;121(1):127-35
pubmed: 17330844
Ann Surg Oncol. 1998 Jul-Aug;5(5):447-51
pubmed: 9718175
Oncotarget. 2016 Jun 21;7(25):38864-38875
pubmed: 27102151

Auteurs

Qiuping Mo (Q)

General Surgery, Cancer Center, Department of Breast Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, China.

Yongzhen Wang (Y)

Department of Breast Surgery, Ninghai Maternal and Child Health Hospital, Ningbo, Zhejiang, China.

JinLan Shan (J)

Department of Breast Surgery, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Xiaochen Wang (X)

Department of Breast Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. wangxiaochen@zju.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH